Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.

Fischer SL, Borner T

Open source

DOI
10.1016/j.phrs.2026.108382
Published
2026 Oct
Container
Pharmacological research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.phrs.2026.108382,
  title = {Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.},
  author = {Fischer SL and Borner T},
  year = {2026},
  journal = {Pharmacological research},
  doi = {10.1016/j.phrs.2026.108382},
  url = {https://doi.org/10.1016/j.phrs.2026.108382}
}

RIS

TY  - JOUR
TI  - Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
AU  - Fischer SL
AU  - Borner T
PY  - 2026
JO  - Pharmacological research
DO  - 10.1016/j.phrs.2026.108382
UR  - https://doi.org/10.1016/j.phrs.2026.108382
ER  - 

APA

SL, F., & T, B. (2026). Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.. Pharmacological research. https://doi.org/10.1016/j.phrs.2026.108382

Source records